Alexander H G Paterson

Summary

Affiliation: Cross Cancer Institute
Country: Canada

Publications

  1. doi request reprint Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
    Alexander H G Paterson
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Lancet Oncol 13:734-42. 2012
  2. pmc Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
    Trevor Powles
    Parkside Oncology, London, UK
    Breast Cancer Res 8:R13. 2006
  3. ncbi request reprint Evaluating bone mass and bone quality in patients with breast cancer
    Alexander H G Paterson
    Tom Baker Cancer Center Calgary, Department of Medicine, 1331 29th St NW, Calgary, AB T2N 4N2, Canada
    Clin Breast Cancer 5:S41-5. 2005
  4. ncbi request reprint The role of bisphosphonates in early breast cancer
    Alexander H G Paterson
    Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada
    Oncologist 11:13-9. 2006
  5. ncbi request reprint Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients
    A Paterson
    Department of Oncology, Tom Baker Cancer Centre, University of Calgary, 1331 29th Street NW, Calgary, Alberta, Canada
    J Int Med Res 36:400-13. 2008
  6. doi request reprint Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials
    John R Mackey
    Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada
    Cancer Treat Rev 38:673-88. 2012
  7. ncbi request reprint Adjuvant clodronate in breast cancer
    Alexander H G Paterson
    Acta Oncol 44:80-2; author reply 83-4. 2005
  8. ncbi request reprint Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases
    Allan Lipton
    Penn State Milton S Hershey Medical Center, Hershey, PA 17033 0850, USA
    J Clin Oncol 25:4431-7. 2007

Collaborators

Detail Information

Publications8

  1. doi request reprint Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial
    Alexander H G Paterson
    National Surgical Adjuvant Breast and Bowel Project, Pittsburgh, PA, USA
    Lancet Oncol 13:734-42. 2012
    ..The National Surgical Adjuvant Breast and Bowel Project (NSABP) protocol B-34 aims to ascertain whether oral clodronate can improve outcomes in women with primary breast cancer...
  2. pmc Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]
    Trevor Powles
    Parkside Oncology, London, UK
    Breast Cancer Res 8:R13. 2006
    ....
  3. ncbi request reprint Evaluating bone mass and bone quality in patients with breast cancer
    Alexander H G Paterson
    Tom Baker Cancer Center Calgary, Department of Medicine, 1331 29th St NW, Calgary, AB T2N 4N2, Canada
    Clin Breast Cancer 5:S41-5. 2005
    ..5 in the presence of a fragility fracture or vertebral compression fracture, or if height loss > 2 cm occurs or BMD decreases > 3% in 1 year at the lumbar spine or > 5% at the femoral neck, bisphosphonate therapy should be considered...
  4. ncbi request reprint The role of bisphosphonates in early breast cancer
    Alexander H G Paterson
    Tom Baker Cancer Centre, University of Calgary, Calgary, Alberta, Canada
    Oncologist 11:13-9. 2006
    ..Patient preference for oral or i.v. therapy will also be assessed...
  5. ncbi request reprint Cost-effectiveness of oral clodronate compared with oral ibandronate, intravenous zoledronate or intravenous pamidronate in breast cancer patients
    A Paterson
    Department of Oncology, Tom Baker Cancer Centre, University of Calgary, 1331 29th Street NW, Calgary, Alberta, Canada
    J Int Med Res 36:400-13. 2008
    ..The UK results were similar, the costs per patient of treatment with oral clodronate being euro841.79, euro2989.99 and euro3669.19 less than with oral ibandronate, intravenous pamidronate and intravenous zoledronate, respectively...
  6. doi request reprint Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials
    John R Mackey
    Cross Cancer Institute, 11560 University Avenue, Edmonton, Alberta, Canada
    Cancer Treat Rev 38:673-88. 2012
    ..Angiogenesis is critical for tumor growth and a promising therapeutic target. This review will summarize and analyze data from clinical trials of anti-angiogenic agents in the treatment of breast cancer (BC)...
  7. ncbi request reprint Adjuvant clodronate in breast cancer
    Alexander H G Paterson
    Acta Oncol 44:80-2; author reply 83-4. 2005
  8. ncbi request reprint Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases
    Allan Lipton
    Penn State Milton S Hershey Medical Center, Hershey, PA 17033 0850, USA
    J Clin Oncol 25:4431-7. 2007
    ..In this study, we evaluated the efficacy and safety of five dosing regimens of denosumab in patients with breast cancer-related bone metastases not previously treated with intravenous bisphosphonates (IV BPs)...